123 related articles for article (PubMed ID: 9042792)
21. VLA2 integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry.
Charpin C; Garcia S; Bergeret D; Andrac L; Horschowski N; Choux R; Lavaut MN
Br J Cancer; 1998 Jun; 77(12):2274-80. PubMed ID: 9649145
[TBL] [Abstract][Full Text] [Related]
22. The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study.
Ma W; Deng Y; Zhou L
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):258-63. PubMed ID: 15997921
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays.
Charpin C; Garcia S; Bonnier P; Martini F; Andrac L; Horschowski N; Lavaut MN; Allasia C
J Pathol; 1998 Apr; 184(4):401-7. PubMed ID: 9664906
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer.
Tempfer C; Lösch A; Heinzl H; Häusler G; Hanzal E; Kölbl H; Breitenecker G; Kainz C
Eur J Cancer; 1996 Oct; 32A(11):2023-5. PubMed ID: 8943691
[TBL] [Abstract][Full Text] [Related]
25. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence.
Gilcrease MZ; Guzman-Paz M; Niehans G; Cherwitz D; McCarthy JB; Albores-Saavedra J
Cancer; 1999 Dec; 86(11):2320-6. PubMed ID: 10590373
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study.
Castellà EM; Ariza A; Ojanguren I; Mate JL; Roca X; Fernández-Vasalo A; Navas-Palacios JJ
Virchows Arch; 1996 Nov; 429(4-5):191-5. PubMed ID: 8972753
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer.
Wu XJ; Li XD; Zhang H; Zhang X; Ning ZH; Yin YM; Tian Y
J Int Med Res; 2015 Apr; 43(2):173-9. PubMed ID: 25571897
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component.
Umeda T; Ishida M; Murata S; Mori T; Kawai Y; Itoi N; Tomida K; Tanaka A; Sakai S; Kitamura M; Kubota Y; Kushima R; Tani M
Breast Cancer; 2016 Nov; 23(6):869-875. PubMed ID: 26494575
[TBL] [Abstract][Full Text] [Related]
29. CD44v6 is not a prognostic factor in primary breast cancer.
Jansen RH; Joosten-Achjanie SR; Arends JW; Volovics A; Hupperets PS; Schouten HC; Hillen HF
Ann Oncol; 1998 Jan; 9(1):109-11. PubMed ID: 9541692
[TBL] [Abstract][Full Text] [Related]
30. ELAM selectin expression in breast carcinomas detected by automated and quantitative immunohistochemical assays.
Charpin C; Bergeret D; Garcia S; Andrac L; Martini F; Horschowski N; Choux R; Lavaut MN
Int J Oncol; 1998 May; 12(5):1041-8. PubMed ID: 9538126
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study.
Morris SF; O'Hanlon DM; McLaughlin R; McHale T; Connolly GE; Given HF
Eur J Surg Oncol; 2001 Sep; 27(6):527-31. PubMed ID: 11520083
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.
Tzankov A; Pehrs AC; Zimpfer A; Ascani S; Lugli A; Pileri S; Dirnhofer S
J Clin Pathol; 2003 Oct; 56(10):747-52. PubMed ID: 14514777
[TBL] [Abstract][Full Text] [Related]
33. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
34. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
Afify A; Purnell P; Nguyen L
Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
[TBL] [Abstract][Full Text] [Related]
35. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas.
Hong RL; Lee WJ; Shun CT; Chu JS; Chen YC
Oncology; 1995; 52(4):334-9. PubMed ID: 7539903
[TBL] [Abstract][Full Text] [Related]
36. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Garcia S; Dalès JP; Charafe-Jauffret E; Carpentier-Meunier S; Andrac-Meyer L; Jacquemier J; Andonian C; Lavaut MN; Allasia C; Bonnier P; Charpin C
Hum Pathol; 2007 Jun; 38(6):830-41. PubMed ID: 17316758
[TBL] [Abstract][Full Text] [Related]
37. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
38. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of Ki 67/MIB1 automated and quantitative immunolabelling in primary operable breast carcinomas.
Charpin C; Garcia S; Bouvier C; Devictor B; Andra L; Lavaut M; Allasia C; Bonnier P
Int J Oncol; 1996 Aug; 9(2):337-44. PubMed ID: 21541520
[TBL] [Abstract][Full Text] [Related]
40. HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases.
Sun H; Liu T; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y
Genes Chromosomes Cancer; 2017 Aug; 56(8):598-607. PubMed ID: 28393427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
